|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Temel JS, Greer JA, Muzikansky A, et al:
Early palliative care for patients with metaSTATic non-small-cell
lung cancer. N Engl J Med. 363:733–742. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yano T, Okamoto T, Fukuyama S and Maehara
Y: Therapeutic strategy for postoperative recurrence in patients
with non-small cell lung cancer. World J Clin Oncol. 5:1048–1054.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hsieh FC, Cheng G and Lin J: Evaluation of
potential Stat3-regulated genes in human breast cancer. Biochem
Biophys Res Commun. 335:292–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Catlett-Falcone R, Landowski TH, Oshiro
MM, et al: Constitutive activation of Stat3 signaling confers
resistance to apoptosis in human U266 myeloma cells. Immunity.
10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grandis JR, Drenning SD, Zeng Q, et al:
Constitutive activation of Stat3 signaling abrogates apoptosis in
squamous cell carcinogenesis in vivo. Proc Natl Acad Sci
USA. 97:4227–4232. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan X, Fraser M, Qiu Q and Tsang BK:
Over-expression of PTEN sensitizes human ovarian cancer cells to
cisplatin-induced apoptosis in a p53-dependent manner. Gynecol
Oncol. 102:348–355. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Epling-Burnette PK, Liu JH,
Catlett-Falcone R, et al: Inhibition of Stat3 signaling leads to
apoptosis of leukemic large granular lymphocytes and decreased
Mcl-1 expression. J Clin Invest. 107:351–362. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mora LB, Buettner R, Seigne J, et al:
Constitutive activation of Stat3 in human prostate tumors and cell
lines: Direct inhibition of Stat3 signaling induces apoptosis of
prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
|
|
12
|
Scholz A, Heinze S, Detjen KM, et al:
Activated signal transducer and activator of transcription 3
(Stat3) supports the malignant phenotype of human pancreatic
cancer. Gastroenterology. 125:891–905. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kanda N, Seno H, Konda Y, et al: Stat3 is
constitutively activated and supports cell survival in association
with survivin expression in gastric cancer cells. Oncogene.
23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li L and Shaw PE: Autocrine-mediated
activation of Stat3 correlates with cell proliferation in breast
carcinoma lines. J Biol Chem. 277:17397–17405. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song L, Turkson J, Karras JG, Jove R and
Haura EB: Activation of Stat3 by receptor tyrosine kinases and
cytokines regulates survival in human non-small cell carcinoma
cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kulesza DW, Carré T, Chouaib S and
Kaminska B: Silencing of the transcription factor Stat3 sensitizes
lung cancer cells to DNA damaging drugs, but not to TNFα- and NK
cytotoxicity. Exp Cell Res. 319:506–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peduto L: ADAM9 as a potential target
molecule in cancer. Curr Pharm Des. 15:2282–2287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duffy MJ, McKiernan E, O'Donovan N and
McGowan PM: Role of ADAMs in cancer formation and progression. Clin
Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shintani Y, Higashiyama S, Ohta M, et al:
Overexpression of ADAM9 in non-small cell lung cancer correlates
with brain metastasis. Cancer Res. 64:4190–4196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Q, Liu X, Cai Y, Yu Y and Chen W:
RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid
cystic carcinoma cells. Tumour Biol. 31:217–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang L, Gong F and Cui Y: RNAi-mediated A
disintegrin and metalloproteinase 9 gene silencing inhibits the
tumor growth of non-small lung cancer in vitro and in vivo. Mol Med
Rep. 12:1197–1204. 2015.PubMed/NCBI
|
|
22
|
Wei EK, Wolin KY and Colditz GA: Time
course of risk factors in cancer etiology and progression. J Clin
Oncol. 28:4052–4057. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiu HC, Chou DL, Huang CT, et al:
Suppression of Stat3 activity sensitizes gefitinib-resistant non
small cell lung cancer cells. Biochem Pharmacol. 81:1263–1270.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu S, Zhang W, Liu K, Wang Y, Ji B and
Liu Y: Synergistic effects of co-expression plasmid-based
ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in
vitro and in vivo. Oncol Rep. 32:2501–2510.
2014.PubMed/NCBI
|
|
25
|
Roberti A: LaS ala D and Cinti C: Multiple
genetic and epigenetic interacting mechanisms contribute to
clonally selection of drug-resistant tumors: Current views and new
therapeutic prospective. J Cell Physiol. 207:571–581. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang GM, Ren ZX, Wang PS, et al:
Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth
of thyroid cancer cells in vitro and in vivo. Oncol
Rep. 32:573–580. 2014.PubMed/NCBI
|
|
27
|
Zhang L, Gao L, Li Y, et al: Effects of
plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M
tumor cell growth. Clin Cancer Res. 14:559–568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Li Y, Hu J, Wang B, Zhao L, Ji K,
Guo B, Yin D, Du Y, Kopecko DJ, et al: Plasmid-based E6-specific
siRNA and co-expression of wild-type p53 suppresses the growth of
cervical cancer in vitro and in vivo. Cancer Lett.
335:242–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li L, Yu C, Ren J, et al: Synergistic
effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1
genes on lung cancer in vitro and in vivo. J Cancer
Res Clin Oncol. 140:895–907. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu Y, Shen Y, Ji B, Wang L, Zhang Z and
Zhang Y: Combinational RNAi gene therapy of hepatocellular
carcinoma by targeting human EGFR and TERT. Eur J Pharm Sci.
42:387–391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen Y, Cao Y, Yang D, et al: Increase of
the therapeutic effect on non-small-cell lung cancer cells with
combination treatment of shRNA against Cyclin D1 and Bcl-xL in
vitro. Exp Ther Med. 3:255–260. 2012.PubMed/NCBI
|
|
32
|
Lai WY, Wang WY, Chang YC, et al:
Synergistic inhibition of lung cancer cell invasion, tumor growth
and angiogenesis using aptamer-siRNA chimeras. Biomaterials.
35:2905–2914. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hanibuchi M, Kim SJ, Fidler IJ and
Nishioka Y: The molecular biology of lung cancer brain metastasis,
An overview of current comprehensions and future perspectives. J
Med Invest. 61:241–253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nguyen DX, Bos PD and Massagué J:
Metastasis. From dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bacac M and Stamenkovic I: Metastatic
cancer cell. Annu Rev Pathol. 3:221–247. 2008. View Article : Google Scholar : PubMed/NCBI
|
